ADA

(redirected from adenosine deaminase)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to adenosine deaminase: Adenosine deaminase deficiency

Americans with Disabilities Act

Legislation in the United States, passed in 1990, that extended civil rights laws to persons who are physically disabled. Among other provisions, it requires facilities to accommodate the disabled insofar as it is possible. Businesses must comply with the Act when they build or expand their buildings. For example, most new commercial buildings with steps are required to provide access for persons who use wheelchairs.

ADA

See Americans with Disabilities Act.
References in periodicals archive ?
Keywords: Combined Immunodeficiency, T and B cell, Gastrointestinal tract infections, Adenosine deaminase.
Pleural fluid adenosine deaminase and lymphocyte proportion: clinical usefulness in the diagnosis of tuberculosis.
Adenosine deaminase activity in serum and placenta of patients with anembryonic pregnancies and missed abortions.
Adenosine deaminase for lymphocytic pleural effusions.
Tumour necrosis factor-alpha, adenosine deaminase and nitric oxide levels in cattle babesiosis before and after treatment.
The adenosine deaminase test is a simple and low-cost procedure that may be included as a routine laboratory method, especially in those countries with a high prevalence of tuberculosis.
Adenosine deaminase levels in csf of tuberculous meningitis patients.
Adenosine deaminase (ADA) is an enzyme which is involved in purine metabolism in which it is responsible for conversation of adenosine and deoxyadenosine to inosine and deoxyinosine respectively resulting in release of ammonia.
The product of recombinant technology, Revcovi eliminates the need to source the enzyme from animals and works by supplementing levels of an essential enzyme called adenosine deaminase.
The portfolio consists of: Strimvelis, the first autologous ex vivo gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID); two late-stage clinical programmes that are in ongoing registrational studies for metachromatic leukodystrophy (MLD) and Wiskott Aldrich syndrome (WAS); and a clinical programme for beta thalassaemia.
After observing the physical appearance of the fluid it was sent for cytological (including detection of malignant cell), microbiological (Gram staining, acid-fast bacilli [AFB] staining, and culture in selected cases) and biochemical tests (glucose, protein, and lactate dehydrogenase [LDH]) including estimation of adenosine deaminase (ADA) where physical appearance of the fluid not seems to be of transudate.

Full browser ?